These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
637 related articles for article (PubMed ID: 29677483)
21. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents. Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750 [TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors. Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467 [TBL] [Abstract][Full Text] [Related]
23. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments. Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739 [TBL] [Abstract][Full Text] [Related]
24. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis. Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808 [TBL] [Abstract][Full Text] [Related]
29. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065 [TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and preclinical evaluation of 5-methyl-N Devambatla RKV; Choudhary S; Ihnat M; Hamel E; Mooberry SL; Gangjee A Bioorg Med Chem Lett; 2018 Oct; 28(18):3085-3093. PubMed ID: 30098869 [TBL] [Abstract][Full Text] [Related]
31. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition. Maher M; Kassab AE; Zaher AF; Mahmoud Z Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080 [TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors. El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731 [TBL] [Abstract][Full Text] [Related]
33. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation. Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640 [TBL] [Abstract][Full Text] [Related]
34. Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect. Sana S; Reddy VG; Bhandari S; Reddy TS; Tokala R; Sakla AP; Bhargava SK; Shankaraiah N Eur J Med Chem; 2020 Aug; 200():112457. PubMed ID: 32422489 [TBL] [Abstract][Full Text] [Related]
35. New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors. Salerno S; García-Argáez AN; Barresi E; Taliani S; Simorini F; La Motta C; Amendola G; Tomassi S; Cosconati S; Novellino E; Da Settimo F; Marini AM; Via LD Eur J Med Chem; 2018 Apr; 150():446-456. PubMed ID: 29547832 [TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058 [TBL] [Abstract][Full Text] [Related]
37. Molecular Design and Synthesis of New 3,4-Dihydropyrimidin-2(1H)-Ones as Potential Anticancer Agents with VEGFR-2 Inhibiting Activity. Mostafa AS; Bayoumi WA; El-Mesery M; Elgaml A Anticancer Agents Med Chem; 2019; 19(3):310-322. PubMed ID: 30019649 [TBL] [Abstract][Full Text] [Related]